Jeremy F L Cobbold1, Sarrah Raveendran1, Christopher M Peake1, Quentin M Anstee2, Michael S Yee3, Mark R Thursz1. 1. Hepatology and Gastroenterology Section, Department of Medicine, Imperial College London, London, UK. 2. Institute of Cellular Medicine, Newcastle University, Newcastle-Upon-Tyne, UK. 3. Department of Diabetes and Endocrinology, Imperial College Healthcare NHS Trust, London, UK.
Abstract
OBJECTIVE: A multidisciplinary approach is advocated for the management of Non-Alcoholic Fatty Liver Disease (NAFLD), but few clinical data exist to support this. The objective of this study was to investigate the effectiveness of a multidisciplinary NAFLD clinic using surrogate markers of liver injury and cardiovascular risk. DESIGN: Retrospective survey of clinical practice. SETTING: The multidisciplinary NAFLD clinic in a secondary/tertiary care setting with hepatology, diabetology, dietetic and exercise therapy input: initial 5-years' experience (2007-2012). PATIENTS: 180 patients with NAFLD but without hepatic comorbidities were followed up for a median of 19.5 (range 3-57) months. 52% had type 2 diabetes mellitus, 48% were Europoid Caucasian, 17% were South Asian. INTERVENTIONS: Multiple clinical interventions were employed including lifestyle (diet and exercise) advice, pharmacological intervention for cardiovascular risk factors, weight loss and exercise therapy. MAIN OUTCOME MEASURES: Change in alanine aminotransferase (ALT), weight, HbA1c, lipid profile and blood pressure. RESULTS: Median ALT fell from 61 (12-270) U/l to 50 (11-221) U/l, -18%, p<0.001, and weight fell from 90.5 (42.7-175.0) kg to 87.3 (45.9-175.3) kg, -3.5%, p<0.001. There were significant improvements in total cholesterol overall, triglycerides (among dyslipidaemic patients), HbA1c (among diabetic patients) and systolic blood pressure (among hypertensive patients). 24% of patients achieved ≥7% weight loss during follow-up and 17% maintained this weight loss throughout. CONCLUSIONS: Improvement in liver biochemistry and cardiovascular risk factors was seen in patients attending the multidisciplinary NAFLD clinic. Refinement of this approach is warranted in light of these data, novel therapies and a growing evidence base.
OBJECTIVE: A multidisciplinary approach is advocated for the management of Non-Alcoholic Fatty Liver Disease (NAFLD), but few clinical data exist to support this. The objective of this study was to investigate the effectiveness of a multidisciplinary NAFLD clinic using surrogate markers of liver injury and cardiovascular risk. DESIGN: Retrospective survey of clinical practice. SETTING: The multidisciplinary NAFLD clinic in a secondary/tertiary care setting with hepatology, diabetology, dietetic and exercise therapy input: initial 5-years' experience (2007-2012). PATIENTS: 180 patients with NAFLD but without hepatic comorbidities were followed up for a median of 19.5 (range 3-57) months. 52% had type 2 diabetes mellitus, 48% were Europoid Caucasian, 17% were South Asian. INTERVENTIONS: Multiple clinical interventions were employed including lifestyle (diet and exercise) advice, pharmacological intervention for cardiovascular risk factors, weight loss and exercise therapy. MAIN OUTCOME MEASURES: Change in alanine aminotransferase (ALT), weight, HbA1c, lipid profile and blood pressure. RESULTS: Median ALT fell from 61 (12-270) U/l to 50 (11-221) U/l, -18%, p<0.001, and weight fell from 90.5 (42.7-175.0) kg to 87.3 (45.9-175.3) kg, -3.5%, p<0.001. There were significant improvements in total cholesterol overall, triglycerides (among dyslipidaemic patients), HbA1c (among diabeticpatients) and systolic blood pressure (among hypertensivepatients). 24% of patients achieved ≥7% weight loss during follow-up and 17% maintained this weight loss throughout. CONCLUSIONS: Improvement in liver biochemistry and cardiovascular risk factors was seen in patients attending the multidisciplinary NAFLD clinic. Refinement of this approach is warranted in light of these data, novel therapies and a growing evidence base.
Authors: Alexis St George; Adrian Bauman; Amanda Johnston; Geoffrey Farrell; Tien Chey; Jacob George Journal: J Gastroenterol Hepatol Date: 2008-12-02 Impact factor: 4.029
Authors: K Kantartzis; C Thamer; A Peter; J Machann; F Schick; C Schraml; A Königsrainer; I Königsrainer; S Kröber; A Niess; A Fritsche; H-U Häring; N Stefan Journal: Gut Date: 2008-12-11 Impact factor: 23.059
Authors: Pouneh Mofrad; Melissa J Contos; Mahmadul Haque; Carol Sargeant; Robert A Fisher; Velimir A Luketic; Richard K Sterling; Mitchell L Shiffman; Richard T Stravitz; Arun J Sanyal Journal: Hepatology Date: 2003-06 Impact factor: 17.425
Authors: Ahmad Moolla; Kenzo Motohashi; Thomas Marjot; Amelia Shard; Mark Ainsworth; Alastair Gray; Rury Holman; Michael Pavlides; John D Ryan; Jeremy W Tomlinson; Jeremy F Cobbold Journal: Frontline Gastroenterol Date: 2019-04-30